Updated:
SymBiosis
Founded with a thesis of geographic and operational symbiosis, the firm maintains offices in six cities spanning the United States and Singapore.
SymBiosis
Founded with a thesis of geographic and operational symbiosis, the firm maintains offices in six cities spanning the United States and Singapore. This structure is designed to source and support portfolio companies across distinct innovation clusters, connecting the biotech hubs of the Northeast corridor with the technology and capital markets of Los Angeles and the international gateway of Singapore. The firm's name reflects its core approach: creating value through interconnectedness between investors, operators, and markets. SymBiosis deploys capital primarily into early-stage biotechnology and life-science companies. The investment strategy combines direct investments with a collaborative syndication model, bringing together co-investors across its six offices to fund rounds. The firm's sector focus encompasses therapeutics, medical devices, and health-tech platforms, with a stage preference for seed through Series A rounds where scientific risk is still a primary driver of valuation. The firm leverages its Philadelphia and Washington presence for proximity to academic research institutions and regulatory agencies, while its New York and Greenwich offices provide access to deep capital markets. The firm is led by a distributed team of investment professionals operating from its six offices. The multi-city footprint is unusual for a firm of its profile, suggesting that each location plays a specific functional role — likely scientific evaluation on the East Coast, capital formation in New York and Greenwich, and deal origination on the West Coast. There is no public information on adjacent vehicles, philanthropic structures, or the firm's total assets under management. What structurally differentiates SymBiosis is its explicit multi-hub model. Rather than centralizing decision-making in a single headquarters, the firm appears to operate as a network of semi-autonomous nodes, each responsible for deal flow within its regional ecosystem. This architecture aims to capture alpha through localized sourcing, an approach that contrasts with the hub-and-spoke model used by most venture firms, and one that depends heavily on internal coordination and trust across offices.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Los Angeles
Corporate office
Los Angeles, CA, United States
Additional offices
Philadelphia · Washington · New York · Greenwich · Singapore
Frequently asked questions
What is SymBiosis's investment focus?
SymBiosis invests in early-stage biotechnology and life-science companies, according to public record. The firm's thesis centers on therapeutics, medical devices, and health-tech platforms at the seed through Series A stages. Its multi-office structure across Los Angeles, Philadelphia, Washington, New York, Greenwich, and Singapore is designed to give it sourcing advantages in academic research hubs and capital markets.
How does SymBiosis source deal flow across its six offices?
The firm's distributed architecture uses each office as a local sourcing node. Philadelphia and Washington provide proximity to major research universities, teaching hospitals, and federal regulatory bodies like the NIH and FDA. West Coast offices in Los Angeles connect the firm to technology crossover opportunities, while New York and Greenwich serve as capital-formation hubs with access to institutional limited partners. Singapore adds an international dimension for Asian co-investors and market access.
Does SymBiosis lead rounds or participate as a co-investor?
SymBiosis operates with a syndication model, collaborating with other venture firms and angel groups across its six-office network to fund portfolio companies. The firm does not publicly disclose whether it consistently leads rounds or prefers to follow, but its distributed structure is built to aggregate co-investors from multiple geographies into each deal. This approach allows the firm to write checks that are larger than a single-office partnership might support.
Who manages investment decisions at SymBiosis?
SymBiosis has not publicly disclosed its management structure, general partners, or investment committee composition. The firm's website and public filings do not name key decision-makers. Allocators conducting due diligence on the firm will need to request this information directly, as it is not available in the public record.
How is SymBiosis different from other early-stage life-science venture firms?
The structural differentiator is SymBiosis's explicit multi-hub model. Most venture firms, even those with multiple offices, centralize investment decisions in a single headquarters. SymBiosis appears to treat its six offices as co-equal nodes, a design that prioritizes localized scientific evaluation and deal origination over centralized portfolio construction. The trade-off is a heavier coordination burden and a narrower margin for error in partner alignment across geographies.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: